US biotech company Baxalta (NYSE: BXLT) is looking at potential alternative suitors for a merger even as the company remains open to a deal with Ireland-headquartered Shire (LSE: SHP), according to media reports.
Even as there is no confirmation of a new offer from Shire yet, Baxalta is looking if there may be any better deals as an alternative to the merger with Shire, reports say.
Further, there are unconfirmed reports that Shire has made a fresh bid for Baxalta. A deal, if successful, will create one of the world's biggest firms in the realm of rare diseases with product sales of around $20 billion by 2020 and double-digit percent annual growth sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze